Top-News

Jazz Pharmaceuticals Aktie News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
170,93 $
+4,02 $
+2,41%
146,80 € 19:41:44 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,36 Mrd. €
Streubesitz
-
KGV
-
neu: Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,34: JZ11LV
Werbung

Jazz Pharmaceuticals News

09:00 Uhr - PR Newswire
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Extensive New Data and Real-​World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-​Resistant Epilepsies at the American ...
02.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-​hrii) Combinations in First-​Line HER2-Positive Locally Advanced or Metastatic ...
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
17.11.25 - PR Newswire
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Positive HERIZON-​GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-​hrii) as HER2-Targeted Agent-​of-Choice and Ziihera Combination Regimens as New Standard of Care ...
11.11.25 - PR Newswire
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
28.10.25 - PR Newswire
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire
22.10.25 - PR Newswire
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 PR Newswire
22.10.25 - PR Newswire
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 PR Newswire
02.10.25 - PR Newswire
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-​Line Maintenance Therapy for Extensive-​Stage Small Cell Lung Cancer PR Newswire
22.09.25 - PR Newswire
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-​World ...
09.09.25 - PR Newswire
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 PR Newswire
06.08.25 - PR Newswire
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »